Jeffrey I. Everitt

9.7k total citations · 1 hit paper
196 papers, 6.5k citations indexed

About

Jeffrey I. Everitt is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Jeffrey I. Everitt has authored 196 papers receiving a total of 6.5k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Molecular Biology, 51 papers in Pulmonary and Respiratory Medicine and 34 papers in Cancer Research. Recurrent topics in Jeffrey I. Everitt's work include Carcinogens and Genotoxicity Assessment (22 papers), Renal and related cancers (21 papers) and Animal testing and alternatives (20 papers). Jeffrey I. Everitt is often cited by papers focused on Carcinogens and Genotoxicity Assessment (22 papers), Renal and related cancers (21 papers) and Animal testing and alternatives (20 papers). Jeffrey I. Everitt collaborates with scholars based in United States, United Kingdom and Canada. Jeffrey I. Everitt's co-authors include Cheryl L. Walker, Douglas C. Wolf, James B. Mangum, Edilberto Bermudez, Thomas L. Goldsworthy, S R Howe, P.M. Hext, Bahman Asgharian, David B. Warheit and Brian A. Wong and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jeffrey I. Everitt

184 papers receiving 6.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines for the welfare and use of animals in cancer research

2010 1.1k citations Jeffrey I. Everitt et al. profile →

Peers

Countries citing papers authored by Jeffrey I. Everitt

Since Specialization

Citations

This map shows the geographic impact of Jeffrey I. Everitt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey I. Everitt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey I. Everitt more than expected).

Fields of papers citing papers by Jeffrey I. Everitt

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey I. Everitt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey I. Everitt. The network helps show where Jeffrey I. Everitt may publish in the future.

Co-authorship network of co-authors of Jeffrey I. Everitt

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey I. Everitt. A scholar is included among the top collaborators of Jeffrey I. Everitt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey I. Everitt. Jeffrey I. Everitt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacious genome editing in infant mice with glycogen storage disease type Ia 2025 ·JCI Insight ·(unknown), (unknown), Thomas W. Beck, Songtao Li, Elizabeth D. Brooks, (unknown), (unknown), (unknown), Sarah Chan, (unknown), David Courtney, Jeffrey I. Everitt, Bryan R. Cullen, Dwight D. Koeberl	0
2	Nrf2 Hyperactivation as a Driver of Radiotherapy Resistance and Suppressed Antitumor Immunity in Head and Neck Squamous Cell Carcinoma 2025 ·Clinical Cancer Research ·Rutulkumar Patel, (unknown), Lixia Luo, Yan Ma, (unknown), Nerissa T. Williams, Jeffrey I. Everitt, (unknown), Patricia Castro, William K. Decker, William Henry Hudson, Jeffrey N. Myers, Vlad C. Sandulache, Mitchell J. Frederick, Yvonne M. Mowery, David G. Kirsch	0
3	Embolization of the Pancreas Using Microspheres: A Proof-of-Safety Study in a Porcine Model 2024 ·Journal of Vascular and Interventional Radiology ·(unknown), Robert Meyerhoff, Jeffrey I. Everitt, Charles Kim	0
4	Optical imaging reveals chemotherapy-induced metabolic reprogramming of residual disease and recurrence 2024 ·Science Advances ·(unknown), (unknown), (unknown), (unknown), (unknown), Olga Ilkayeva, (unknown), (unknown), Jeffrey I. Everitt, James V. Alvarez, Gregory M. Palmer, Matthew D. Hirschey, Nirmala Ramanujam	5
5	Leptin augments IL-13–induced airway eotaxins and submucosal eosinophilia in obesity-associated asthma 2024 ·Journal of Allergy and Clinical Immunology ·Jennifer L. Ingram, (unknown), Johannes M. Weiss, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Maor Sauler, Njira Lugogo, Mary E. Sunday, Jeffrey I. Everitt, Julia K. L. Walker, Robert M. Tighe, Monica Kraft, Loretta G. Que	1
6	MR histology reveals tissue features beneath heterogeneous MRI signal in genetically engineered mouse models of sarcoma 2024 ·Frontiers in Oncology ·Stephanie J. Blocker, Yvonne M. Mowery, Jeffrey I. Everitt, (unknown), Gary P. Cofer, Yi Qi, (unknown), Eric S. Xu, David G. Kirsch, Cristian T. Badea, G. Allan Johnson	0
7	Targeting glutamine dependence with DRP‐104 inhibits proliferation and tumor growth of castration‐resistant prostate cancer 2023 ·The Prostate ·David Moon, (unknown), (unknown), (unknown), Lingfan Xu, Fan Zhang, Xia Gao, Robert Wild, Jeffrey I. Everitt, Everardo Macias, Yiping He, Jiaoti Huang	6
8	Neoadjuvant Radiation Therapy and Surgery Improves Metastasis-Free Survival over Surgery Alone in a Primary Mouse Model of Soft Tissue Sarcoma 2022 ·Molecular Cancer Therapeutics ·Rutulkumar Patel, Yvonne M. Mowery, Yi Qi, (unknown), Matt Holbrook, Eric S. Xu, Cierra S. Hong, Jonathon E. Himes, Nerissa T. Williams, Jeffrey I. Everitt, Yan Ma, Lixia Luo, Sara R. Selitsky, Jennifer L. Modliszewski, Junheng Gao, Sin‐Ho Jung, David G. Kirsch, Cristian T. Badea	4
9	Cas13d knockdown of lung protease Ctsl prevents and treats SARS-CoV-2 infection 2022 ·Nature Chemical Biology ·Zhifen Cui, Cong Zeng, Furong Huang, Fuwen Yuan, Jinyue Yan, Yue Zhao, Yufan Zhou, William Hankey, Victor X. Jin, Jiaoti Huang, Herman F. Staats, Jeffrey I. Everitt, Gregory D. Sempowski, Hongyan Wang, Yizhou Dong, Shan‐Lu Liu, Qianben Wang	39
10	β-Cyclodextrin-containing polymer treatment of cutaneous lupus and influenza improves outcomes 2021 ·Molecular Therapy ·(unknown), Lyra B. Olson, Rachel E. Rempel, Jeffrey I. Everitt, Dana J. Levine, Smita K. Nair, Mark E. Davis, Bruce A. Sullenger	9
11	The Role of Machine Learning in Cardiovascular Pathology 2021 ·Canadian Journal of Cardiology ·Carolyn Glass, Kyle J. Lafata, William R. Jeck, Roarke Horstmeyer, (unknown), Jeffrey I. Everitt, (unknown), David Dov, Michael A. Seidman	11
12	A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma 2020 ·Cancers ·Jason A. Somarelli, Gabrielle Rupprecht, (unknown), (unknown), Sneha Rao, Dharshan Sivaraj, Alexander L. Lazarides, (unknown), Maya U. Sheth, (unknown), So Young Kim, Kathryn E. Ware, Anika Agarwal, (unknown), Laura E. Selmic, Jeffrey I. Everitt, Shannon J. McCall, (unknown), William C. Eward, David S. Hsu	13
13	Distinct Angiogenic Changes during Carcinogenesis Defined by Novel Label-Free Dark-Field Imaging in a Hamster Cheek Pouch Model 2017 ·Cancer Research ·(unknown), (unknown), (unknown), Jeffrey I. Everitt, Alaattin Erkanli, Walter T. Lee, Mark W. Dewhirst, Nirmala Ramanujam	6
14	Environmental Estrogens Differentially Engage the Histone Methyltransferase EZH2 to Increase Risk of Uterine Tumorigenesis 2012 ·Molecular Cancer Research ·K. Leigh Greathouse, Tiffany Bredfeldt, Jeffrey I. Everitt, Kevin Lin, Tia Berry, Kurunthachalam Kannan, (unknown), Shuk‐Mei Ho, Cheryl L. Walker	128
15	The Art and Science of Introducing Animals to the Research Environment 2006 ·ILAR Journal ·Jeffrey I. Everitt, (unknown)	1
16	Pulmonary Responses of Mice, Rats, and Hamsters to Subchronic Inhalation of Ultrafine Titanium Dioxide Particles 2003 ·Toxicological Sciences ·Edilberto Bermudez, James B. Mangum, Brian A. Wong, Bahman Asgharian, P.M. Hext, David B. Warheit, Jeffrey I. Everitt	467
17	Promotion by sodium barbital induces early development but does not increase the multiplicity of hereditary renal tumors in Eker rats 2000 ·Carcinogenesis ·Douglas C. Wolf, Thomas L. Goldsworthy, Derek B. Janszen, (unknown), Erica Donner, (unknown), Jeffrey I. Everitt	8
18	Advances in Uterine Leiomyoma Research: Conference Overview, Summary, and Future Research Recommendations 2000 ·Environmental Health Perspectives ·Retha R. Newbold, Richard P. DiAugustine, John I. Risinger, Jeffrey I. Everitt, David K. Walmer, Estella C. Parrott, Darlene Dixon	35
19	Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha- and gamma-adducin during renal tumor progression. 1998 ·PubMed ·(unknown), Jeffrey I. Everitt, James Stevens, Susan Jaken	24
20	Metiamide--absence of presynaptic alpha-adrenoceptor antagonist properties in the pithed rat [proceedings]. 1979 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·John C. Doxey, Jeffrey I. Everitt	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact